Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâre developing a new type of targeted therapy that ââŚrelies on knowledge from an RNA-based diagnostic instead of more traditional DNA-based diagnostics to determine if a patient with cancer is a candidate for our targeted therapy.â They believe that this type of diagnostic will help unlock targeted therapies for the 70% of cancer patients who do not have âdruggableâ genetic mutations in their DNA. So far, Nemucore has raised $7M from foundation grants and the National Cancer Institute; they have over 57 investors; and leading experts at Memorial Sloan Kettering and Moffitt Cancer Centers are set to perform their clinical trial. Plus, their leadership team has over 100 years of biopharmaceutical experience. The bottom line? Nemucore wants, with this campaign, to âcure AML together and open a new future of cancer care.â Source
No articles found.
MYOS RENS Technology, Inc. (NASDAQ: MYOS), a company based in Cedar Knolls, NJ was...
MYOS RENS Technology, Inc. (NASDAQ: MYOS), a co...
We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a n...
We are a clinical stage biopharmaceutical compa...
LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in Nutrigenomics - a new scien...
LifeVantage Corporation (Nasdaq: LFVN) is a pio...
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicat...
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI...
With demonstrated clinical development and commercialization expertise, VIVUS is d...
With demonstrated clinical development and comm...
Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company...
Alimera Sciences (NASDAQ: ALIM), founded in Jun...
Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focuse...
Stemline Therapeutics, Inc. is a commercial-sta...
Join the National Investor Network and get the latest information with your interests in mind.